NASDAQ: ALZN - Alzamend Neuro, Inc.

半年間の収益性: +76.28%
セクタ: Healthcare

プロモーションスケジュール Alzamend Neuro, Inc.


会社について

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.

さらに詳しく
The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

EBITDA -0.005
Число акций ао 0.0065 млрд
P/BV 6.81
EV/EBITDA 0.0085
Цена ао 0.9952
ISIN US02262M3088
Сайт https://www.alzamend.com
Валюта usd
IPO date 2021-06-15
Sector Health Care
Industry Biotechnology
Валюта отчета usd
1日あたりの価格変動: -1.23% (1.63)
週ごとの価格変動: -9.04% (1.77)
月ごとの料金変更: -26.48% (2.19)
3ヶ月間の価格変動: +250% (0.46)
半年間の価格変動: +76.28% (0.9133)
年間の価格変動: +606.14% (0.228)
3年間の価格推移: -32.92% (2.4)
年初からの価格変動: +18.38% (1.36)

過小評価

名前 意味 学年
P/S 0 0
P/BV 1.79 8
P/E 0 0
EV/EBITDA -0.0216 0
合計: 3.5

効率

名前 意味 学年
ROA, % -251.51 0
ROE, % -488.53 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA 0 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % 0 0
収益性 Ebitda, % 124.7 10
収益性 EPS, % 29906.76 10
合計: 8



スーパーバイザー 役職 支払い 生年
Mr. Stephan Jackman CEO & Director 434.24k 1976 (48 年)
Mr. David J. Katzoff Chief Financial Officer 116.67k 1962 (62 年)
Mr. Henry C. W. Nisser Esq. Executive VP, General Counsel & Director 50k 1969 (55 年)
Mr. Milton Charles Ault III Founder & Vice Chairman N/A 1970 (54 年)

住所: United States, Atlanta. GA, 3480 Peachtree Road NE - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.alzamend.com